Some of the brand names: Wegovy, Ozempic, Zepbound, Mounjaro
22 As such, if these drugs gain approval, it logically follows that pediatric obesity could become one of these conditions, leading to widespread use and availability of these medications to an already vulnerable population
Thus, all current evidence points to the suppression of energy intake being the underlying mechanism responsible for the beneficial effects of GLP-1R agonists on body weight in patients with obesity and/or T2D
Retrieved from Ghusn, W., De la Rosa, A., Sacoto, D., et al
Understanding what might be influencing your results can help you have a more informed conversation with your healthcare provider
The timeline you need to know There is good news buried in the data